FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563278394> ?p ?o ?g. }

• W2563278394 endingPage "91" @default.
• W2563278394 startingPage "91" @default.
• W2563278394 abstract "Abstract Background: The combination of lenalidomide and dexamethasone (RD) has been shown to be highly effective as initial therapy for multiple myeloma. More recently, a phase III trial demonstrated improved survival with use of lenalidomide and low dose dexamethasone (Rd). Further improvements by incorporating other active agents may increase the depth of response and may improve long-term outcome. We report the results from a phase II trial combining lenalidomide and low dose dexamethasone with cyclophosphamide (RCd) as initial therapy for newly diagnosed MM. Methods: The trial was initiated in July 2006 and completed the initial target accrual of 33 patients by July 2007 (Cohort 1). Due to high rate of dose reductions in cohort 1, between July 2007 and May 2008 an additional 20 patients were enrolled with lower doses of cyclophosphamide (Cohort 2). The treatment protocol consisted of lenalidomide given orally at a dose of 25 mg daily on days 1–21 of a 28-day cycle. Dex was given orally at a dose of 40 mg on days 1, 8, 15, and 22 of each cycle. Cyclophosphamide at a dose of 300 mg/m2 was given on days 1, 8, and 15 of each cycle in cohort 1 and 300 mg on days 1, 8, and 15 of each cycle in cohort 2. Patients also received an aspirin once daily as thromboprophylaxis. Response was defined as a decrease in serum monoclonal (M) protein by 50% or higher and a decrease in urine M protein by at least 90% or to a level less than 200 mg/24 hours. Responses were assessed on intent to treat basis. Results: 53 patients were enrolled. The median age was 64 years (range, 37–82). 14 patients (29%) had ISS stage III disease. The median number of cycles was 4 (range: 1 – 20). The best response based on all enrolled patients on an intent to treat basis was 83%, including CR:1 (2%), VGPR: 20 (38%), PR: 23 (43%), and less than PR: 9 (17%). The CR plus VGPR rate was 40%. Among the 20 patients in cohort 2 who were enrolled after optimization of the cyclophosphamide dosing, 16 (80%) have already achieved a partial response or better with 17 patients in this cohort still receiving study treatment. Overall, 25 of the 53 enrolled patients have discontinued study treatment. Reasons for ending treatment are: completed study per protocol (14), disease progression (5), adverse event (3) and alternate treatment (3). This includes 3 patients from cohort 2, one completed treatment per protocol, one went to alternate therapy and one patient went off for progression. Hematological toxicity was the most common with grade 4 toxicity seen in 8 patients (only 1 from cohort 2). Non-hematological toxicities included neuropathy, diarrhea, cystitis, and thrombosis. There were 6 patients with grade 4 non-hematological toxicities (none from cohort 2) attributed to the drug (thrombosis, confusion, depression and sepsis). Thirteen patients had dose adjustments, most commonly due to hematological toxicity attributed to lenalidomide or cyclophosphamide. One patient has died off study, of intracranial hemorrhage. The median follow-up for the remaining patients is 7.8 months. Conclusions: The combination of lenalidomide, cyclophosphamide, and dexamethasone (RCd) has excellent activity in the setting of newly diagnosed myeloma. Seventeen patients continue on study and the response rates are likely to be higher with additional followup. Myelosuppression was a significant toxicity leading to dose reductions and cycle delays, and is lower with decreased dose of CTX in cohort 2 without any apparent loss of responses." @default.
• W2563278394 created "2017-01-06" @default.
• W2563278394 creator A5000308170 @default.
• W2563278394 creator A5001453763 @default.
• W2563278394 creator A5003015868 @default.
• W2563278394 creator A5004152557 @default.
• W2563278394 creator A5011926212 @default.
• W2563278394 creator A5012403700 @default.
• W2563278394 creator A5012884078 @default.
• W2563278394 creator A5019526963 @default.
• W2563278394 creator A5021326343 @default.
• W2563278394 creator A5023193953 @default.
• W2563278394 creator A5026574827 @default.
• W2563278394 creator A5027394636 @default.
• W2563278394 creator A5035875752 @default.
• W2563278394 creator A5036150860 @default.
• W2563278394 creator A5051470930 @default.
• W2563278394 creator A5052346975 @default.
• W2563278394 creator A5055467873 @default.
• W2563278394 creator A5058688409 @default.
• W2563278394 creator A5066940168 @default.
• W2563278394 creator A5072775789 @default.
• W2563278394 creator A5076611748 @default.
• W2563278394 date "2008-11-16" @default.
• W2563278394 modified "2023-09-28" @default.
• W2563278394 title "Phase II Trial of Lenalidomide (Revlimid™) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma" @default.
• W2563278394 doi "https://doi.org/10.1182/blood.v112.11.91.91" @default.
• W2563278394 hasPublicationYear "2008" @default.
• W2563278394 type Work @default.
• W2563278394 sameAs 2563278394 @default.
• W2563278394 citedByCount "11" @default.
• W2563278394 countsByYear W25632783942012 @default.
• W2563278394 countsByYear W25632783942013 @default.
• W2563278394 crossrefType "journal-article" @default.
• W2563278394 hasAuthorship W2563278394A5000308170 @default.
• W2563278394 hasAuthorship W2563278394A5001453763 @default.
• W2563278394 hasAuthorship W2563278394A5003015868 @default.
• W2563278394 hasAuthorship W2563278394A5004152557 @default.
• W2563278394 hasAuthorship W2563278394A5011926212 @default.
• W2563278394 hasAuthorship W2563278394A5012403700 @default.
• W2563278394 hasAuthorship W2563278394A5012884078 @default.
• W2563278394 hasAuthorship W2563278394A5019526963 @default.
• W2563278394 hasAuthorship W2563278394A5021326343 @default.
• W2563278394 hasAuthorship W2563278394A5023193953 @default.
• W2563278394 hasAuthorship W2563278394A5026574827 @default.
• W2563278394 hasAuthorship W2563278394A5027394636 @default.
• W2563278394 hasAuthorship W2563278394A5035875752 @default.
• W2563278394 hasAuthorship W2563278394A5036150860 @default.
• W2563278394 hasAuthorship W2563278394A5051470930 @default.
• W2563278394 hasAuthorship W2563278394A5052346975 @default.
• W2563278394 hasAuthorship W2563278394A5055467873 @default.
• W2563278394 hasAuthorship W2563278394A5058688409 @default.
• W2563278394 hasAuthorship W2563278394A5066940168 @default.
• W2563278394 hasAuthorship W2563278394A5072775789 @default.
• W2563278394 hasAuthorship W2563278394A5076611748 @default.
• W2563278394 hasConcept C126322002 @default.
• W2563278394 hasConcept C126894567 @default.
• W2563278394 hasConcept C141071460 @default.
• W2563278394 hasConcept C2776063141 @default.
• W2563278394 hasConcept C2776364478 @default.
• W2563278394 hasConcept C2776694085 @default.
• W2563278394 hasConcept C2776755627 @default.
• W2563278394 hasConcept C2780401358 @default.
• W2563278394 hasConcept C71924100 @default.
• W2563278394 hasConcept C72563966 @default.
• W2563278394 hasConcept C90924648 @default.
• W2563278394 hasConceptScore W2563278394C126322002 @default.
• W2563278394 hasConceptScore W2563278394C126894567 @default.
• W2563278394 hasConceptScore W2563278394C141071460 @default.
• W2563278394 hasConceptScore W2563278394C2776063141 @default.
• W2563278394 hasConceptScore W2563278394C2776364478 @default.
• W2563278394 hasConceptScore W2563278394C2776694085 @default.
• W2563278394 hasConceptScore W2563278394C2776755627 @default.
• W2563278394 hasConceptScore W2563278394C2780401358 @default.
• W2563278394 hasConceptScore W2563278394C71924100 @default.
• W2563278394 hasConceptScore W2563278394C72563966 @default.
• W2563278394 hasConceptScore W2563278394C90924648 @default.
• W2563278394 hasIssue "11" @default.
• W2563278394 hasLocation W25632783941 @default.
• W2563278394 hasOpenAccess W2563278394 @default.
• W2563278394 hasPrimaryLocation W25632783941 @default.
• W2563278394 hasRelatedWork W1804942062 @default.
• W2563278394 hasRelatedWork W1965304510 @default.
• W2563278394 hasRelatedWork W2004833090 @default.
• W2563278394 hasRelatedWork W2097226850 @default.
• W2563278394 hasRelatedWork W2146492579 @default.
• W2563278394 hasRelatedWork W2297717779 @default.
• W2563278394 hasRelatedWork W2346728206 @default.
• W2563278394 hasRelatedWork W3082115241 @default.
• W2563278394 hasRelatedWork W4221041711 @default.
• W2563278394 hasRelatedWork W2182322203 @default.
• W2563278394 hasVolume "112" @default.
• W2563278394 isParatext "false" @default.
• W2563278394 isRetracted "false" @default.
• W2563278394 magId "2563278394" @default.
• W2563278394 workType "article" @default.